Guardant Health(US:GH) Financial Modeling Prep·2026-02-23 20:06Core Viewpoint - Guardant Health is a significant player in precision oncology, focusing on blood tests for cancer detection and treatment, with recent positive ratings from analysts and mixed investor actions [1][5]. Investment Ratings - Raymond James upgraded Guardant Health to "Outperform" with a price target increase from $115 to $129, reflecting confidence in the company's future performance [1][5]. Investor Actions - Granite Investment Partners LLC reduced its stake in Guardant Health by 52.1%, now holding 185,301 shares valued at approximately $11.6 million, contrasting with other investors [2][5]. - Norges Bank acquired a new stake in Guardant Health worth around $64.1 million during the second quarter [3]. - Franklin Resources Inc. increased its investment by 78.2%, now holding 2,319,947 shares valued at $120.7 million after purchasing an additional 1,018,144 shares [3]. - Invesco Ltd. expanded its holdings by 27.3% during the undefined quarter [3]. Stock Performance - The current stock price for Guardant Health is approximately $100.42, reflecting a decrease of about 2.60%, with fluctuations between a low of $100.29 and a high of $103.58 [4]. - Over the past year, the stock has reached a high of $120.74 and a low of $34.88, with a market capitalization of approximately $13.04 billion and a trading volume of around 274,345 shares [4].